Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis

Leukemia

Volumn 24, Issue 4, 2010, Pages 748-755

  Matsuoka, A ^a   Tochigi, A ^a   Kishimoto, M ^a   Nakahara, T ^a   Kondo, T ^a   Tsujioka, T ^a   Tasaka, T ^a   Tohyama, Y ^b   Tohyama, K ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

Cytokinesis; Del(5q); Lenalidomide; Myelodysplastic syndrome

Indexed keywords

AURORA B KINASE; CHROMOSOME PROTEIN; CITRON KINASE; KINESIN; LENALIDOMIDE; MYOSIN HEAVY CHAIN; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; PROTEIN KIF20A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE M PHASE; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOKINESIS; DNA DETERMINATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE LOCATION; HUMAN; HUMAN CELL; MULTINUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PLOIDY; PRIORITY JOURNAL; PROTEIN FAMILY;

EID: 77950925065     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.296     Document Type: Article

References (39)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-1660.
2. Olney HJ, Le Beau MM. The cytogenetics of myelodys-plastic syndromes. Best Pract Res Clin Haematol 2001; 14: 479-495.
3. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no.5 chromosome. Nature 1974; 251: 437-438.
4. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes. In: Swerdlow SH, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008, 87-107.
5. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 2002; 99: 4638-4641.
6. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodys-plastic syndromes and del(5q) including band q31. Leukemia 2004; 18: 113-119.
7. Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406-11411.
8. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13: 78-83.
9. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110: 719-726.
10. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008; 451: 335-339.
11. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979.
12. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166-1172.
13. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
14. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW et al. Schnetkamp PPEnhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immuno-modulatory drugs. J Pharmacol Exp Ther 2003; 305: 1222-1232.
15. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
16. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9: 1625-1630.
17. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
18. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849-858.
19. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
20. Nakamura S, Ohnishi K, Yoshida H, Shinjo K, Takeshita A, Tohyama K et al. Retrovirus-mediated gene transfer of granulocyte colony-stimulating factor receptor (G-CSFR) cDNA into MDS cells and induction of their differentiation by G-CSF. Cytokines Cell Mol Ther 2000; 6: 61-70.
21. Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Brit J Haematol 1994; 87: 235-242.
22. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. Leuk Res 2009; 33: 1011-1016.
23. Bonnet J, Coopman P, Morris MC. Characterization of centrosomal localization and dynamics of Cdc25C phosphatase in mitosis. Cell Cycle 2008; 7: 1991-1998.
24. Tsujioka T, Tochigi A, Kishimoto M, Kondo T, Tasaka T, Wada H et al. DNA ploidy and cell cycle analyses in the bone marrow cells of patients with megaloblastic anemia using laser scanning cytometry. Cytometry B Clin Cytometry 2008; 74: 104-109.
25. Shi Y, Tohyama Y, Kadono T, He J, Shahjahan Miah SM, Hazama R et al. Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis. Blood 2006; 107: 4554-4562.
26. Nigg EA. Origins and consequences of centrosome aberrations in human cancers. Int J Cancer 2006; 119: 2717-2723.
27. Glotzer M. The molecular requirements for cytokinesis. Science 2005; 307: 1735-1739.
28. Guse A, Mishima M, Glotzer M. Phosphorylation of ZEN-4/MKLP1 by aurora B regulates completion of cytokinesis. Curr Biol 2005; 15: 778-786.
29. Echard A, Jollivet F, Martinez O, Lacapère JJ, Rousselet A, Janoueix-Lerosey I et al. Interaction of a Golgi-associated kinesin-like protein with Rab6. Science 1998; 279: 580-585.
30. Fontijn RD, Goud B, Echard A, Jollivet F, van Marle J, Pannekoek H et al. The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis. Mol Cell Biol 2001; 21: 2944-2955.
31. Gruneberg U, Neef R, Honda R, Nigg EA, Barr FA. Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2. J Cell Biol 2004; 166: 167-172.
32. Kaiser BK, Zimmerman ZA, Charbonneau H, Jackson PK. Disruption of centrosome structure, chromosome segregation, and cytokinesis by misexpression of human Cdc14A phosphatase. Mol Biol Cell 2002; 13: 2289-2300.
33. Ganem NJ, Pellman D. Limiting the proliferation of polyploid cells. Cell 2007; 131: 437-440.
34. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 2001; 12: 1315-1328.
35. Giagounidis AAN, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005; 84: 569-571.
36. Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T et al. Myelodysplastic syndrome (MDS) with chromosome 5 abnormalities: a nation-wide survey in Japan. Leukemia 2008; 22: 1874-1881.
37. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 2009; 115: 5202-5209.
38. Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet 2008; 187: 101-111.
39. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyo-types other than deletion 5q. Blood 2008; 111: 86-93.